Myriocin (a de novo ceramide synthesis inhibitor) treated mice exhibited a reduced ceramide content in the liver resulting in improved hepatic insulin signaling (13, 29), thereby proposing ceramide synthesis as a novel and promising target for the treatment of obesity-associated insulin resistance. This evidence concerns the gene INS and obesity disorder.